Korea Investment Partners

Korea Investment Partners is one of the largest and most established venture firms in South Korea, operating from Seoul as the venture arm of the Korea Investment Holdings group. The firm runs a multi-stage practice that spans seed through growth and maintains active healthcare exposure across biotech, AI in healthcare, and medical devices, with a portfolio that has historically included some of the more visible Korean drug developers and clinical software companies.

The healthcare thesis is broad and pipeline-driven rather than narrowly thematic. The firm allocates across multiple sector funds, including dedicated biotech and healthcare vehicles, and is willing to back companies at the earliest institutional rounds as well as participate in growth rounds preceding public listings. Areas of particular activity include AI analytics applied to medical imaging and clinical data, cell and gene therapy platforms, and oncology drug developers pursuing both Korean and international approvals. The firm’s scale allows it to take meaningful positions and follow on aggressively in companies that perform, which matters in a Korean biotech market where capital intensity has risen substantially over the past decade.

Check sizes commonly fall in the one to five million dollar range at entry, with significant follow-on capacity that allows the firm to maintain ownership through growth rounds. KIP invests from seed through growth, with the bulk of capital deployed at Series A and B. Geographic focus is primarily Korea, with active engagement in cross-border deals where Korean founders or operations are central. The firm’s KOSDAQ listing experience is one of its most concrete advantages for biotech founders considering a domestic IPO path.

The team is large by Korean standards and organized into sector-specialized investment groups, which means healthcare deals are owned by partners who carry biotech or medtech portfolios rather than rotating generalists. Investment committee discipline is real but the firm’s scale and history make decision-making predictable for founders who have prepared their materials carefully.

For founders, KIP functions as a foundational Korean institutional partner that can carry a company from early funding through public listing, which is a relatively rare profile globally. The firm’s value-add is most concentrated around capital markets readiness, syndicate construction with other Korean and Asian institutional investors, and introductions to Korean strategics and pharma partners. Post-investment engagement is steady rather than founder-intensive; partners take board seats where appropriate and weigh in at major decisions but typically let strong management teams run their companies. Founders looking for a hands-on operating partner who will live inside their go-to-market metrics will find the relationship lighter than that, but for Korean biotech, AI healthcare, and medtech founders building toward a serious commercial or capital markets outcome, KIP is one of the firms that can credibly underwrite the full arc.